Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

摘要

Purpose: Concurrent inhibition of multiple oncogenic signaling pathways might improve the efficacy of antieancer agents and abrogate resistance mechanisms. This phase I study evaluated temsirolimus in combination with sunitinib in patients with advanced RCG. Patients and Methods: Eligibility. included advanced RCC and <=2 previous systemic regimens. At the starting dose, temsirolimus 15 mg was administered by intravendus (I.V.) infusion once weekly, and sunitinib. 25 mg was administered orally once daily for 4 weeks, followed by a 2-week rest period.